###### Strengths and limitations of this study

-   Our study will describe the totality of evidence regarding pre-exposure prophylaxis (PrEP) studies in terms of design and characteristics of the studies currently published in the literature.

-   Our scoping review will map the PrEP research literature by identifying knowledge gaps and understudied populations in the PrEP research literature.

-   Our search is limited to studies published in English only, and our review cannot rule out publication bias.

Introduction {#s1}
============

Approximately 36.7 million people are living with HIV globally; about 1.8 million are infected with HIV every year.[@R1] The Joint United Nations Programme on HIV/AIDS released the HIV strategic plan, 'Getting to Zero'[@R2] to achieve the United Nations Millennium Development Goals.[@R3] One of their goals is to achieve zero new HIV infections by cutting the number of sexual transmission events in half, eliminating vertical transmission and preventing HIV transmission among substance users.[@R2]

Pre-exposure prophylaxis (PrEP) plays an important role in achieving the goal of zero new HIV infections. The daily oral HIV PrEP pill, emtricitabine/tenofovir (Truvada), is known to reduce HIV acquisition in clinical trials as well as community-based ('real-world') studies.[@R4] In 2012, the USA was the first country to approve Truvada for use as PrEP and the WHO released the first PrEP clinical practice guideline.[@R8]

Following PrEP's approval and introduction of the WHO guideline, the PrEP-related research literature grew significantly. As the effectiveness of PrEP was established, behavioural and structural factors associated with PrEP are becoming important to understand. For example, PrEP effectiveness is strongly related to behavioural factors such as medication adherence.[@R4] Persons using PrEP may be engaging in more condomless sex and other high-risk behaviours compared with non-PrEP users.[@R9] In addition, new administration and dosage schedules for PrEP have been introduced; these include other types of drugs (eg, tenofovir only, cabotegravir), dose (eg, on demand, four times a week) and routes (eg, topical gel, injectable).[@R10] These new ideas have initiated other areas for research and evaluation, and the PrEP literature has grown considerably over the last decade.

To better understand this emerging research area and explore research gaps, we will conduct a scoping review of the PrEP research literature. The objective of a scoping review is to identify the most common topics studied and evidence gaps in the literature.[@R13] To our knowledge, no scoping review on the PrEP research literature has been published to date. In this protocol, we will provide information on the objectives of the scoping review, search strategy details, study selection and inclusion, and plans for data abstraction and analysis. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols checklist for reporting (see online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}).[@R14]
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Study objectives {#s2}
================

The purpose of our scoping review is to explore the type and extent of the research literature available on PrEP. The specific objectives are to:Identify and map the most common topic areas.Classify study characteristics (study years, countries, population characteristics and designs).Identify research gaps.

Methods and analysis {#s3}
====================

Methodology {#s3a}
-----------

We will use the scoping review methodological framework introduced by Arksey and O'Malley[@R13] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews statement checklist as a guideline to structure the scoping review.[@R15] Scoping review methodology is similar to that of systematic reviews; thus, we will apply established systematic review techniques to locate, screen, assess and abstract data to identify topic areas and research gaps.

Search strategy {#s3b}
---------------

We developed a systematic literature search to identify PrEP-related citations. A subject matter expert identified 24 'gold standard' citations in the PrEP literature. The expert was the United States Centres for Disease Control and Prevention (CDC) physician epidemiologist who is the lead author of the CDC PrEP clinical guideline and has extensively published on PrEP.

A librarian examined these citations to identify possible PrEP keywords and phrases. Search terms were tested to pinpoint essential keywords and Medial Subject Headings (MeSH; indexing) terms. The strategy captures citations on infectious diseases (HIV, sexually transmitted infections (STI) or hepatitis C) cross-referenced against PrEP terms (pre-exposure prophylaxis, chemoprophylaxis) published since 2000 with no language restriction. The full search was first developed in MEDLINE (OVID). Once finalised, the MEDLINE search was tailored to other database's unique indexing in EMBASE (OVID), PsycINFO (OVID) and CINAHL (EBSCOhost) (see online [supplementary appendix 2](#SP1){ref-type="supplementary-material"}).

All citations retrieved with the searches were uploaded to the CDC HIV/AIDS Prevention Research Synthesis (PRS) Project database. This unique comprehensive database includes citations related to HIV, AIDS and STI prevention. We conduct annual electronic and manual searching of numerous databases to upload newly published studies on these topics. The process of creating a comprehensive systematic literature search strategy for the PRS database has been published elsewhere.[@R16] As of November 2018, \>92 000 related citations were included in the PRS database.

Identifying relevant studies {#s3c}
----------------------------

We will search the PRS database for PrEP-related citations. PRS staff will identify HIV PrEP citations by reviewing titles and abstracts. All identified citations will be exported to the systematic review software DistillerSR (Evidence Partners, Ottawa, Canada) for data management, citation screening and data abstraction.

Inclusion criteria for this review are primary studies: (1) focusing on PrEP to prevent HIV, (2) using human subjects and (3) published in English. We will exclude systematic reviews and literature reviews, commentaries, guidelines, protocols, letters to editors, laboratory (eg, in vitro) or preclinical studies (eg, animal studies), grey literature (eg, newsletters) and conference abstracts. Research studies estimating drug efficacy and/or drug resistance for people living with HIV as well as studies focused on PrEP to prevent diseases other than HIV (eg, other STI) will be also excluded.

A three-step approach will be used to identify eligible studies. First, one reviewer will screen the citations by title and abstract to identify those that are related to PrEP and published in English. Citations that are excluded by the reviewer will be verified by a second reviewer. Second, two reviewers will independently review the full text of the included citation to determine whether the primary study was conducted with humans. We will also exclude ineligible studies (eg, systematic reviews) at this level. Disagreements will be resolved through discussion. Finally, if there is a lack of agreement between the two reviewers, a third reviewer will resolve the discrepancy. All forms will be pilot tested and revised as necessary.

Data abstraction {#s3d}
----------------

For eligible citations, two reviewers will independently abstract data on author names, publication year, countries, population characteristics, design and topics. We will abstract study population characteristics using the primary study's inclusion criteria and identify study topics by reviewing the stated purposes or objectives. When the pair of reviewers fail to reach agreement, a third reviewer will resolve the discrepancy.

Mapping study topics {#s3e}
--------------------

To map study topics, we developed preliminary codes and categories ([table 1](#T1){ref-type="table"}). First, we generated initial codes to describe the study topics via literature reviews and consultations with the subject matter experts. These experts included the CDC physician epidemiologist who helped us develop the search strategy and another CDC behavioural scientist with PrEP expertise evidenced in numerous publications. A code succinctly describes or represents a phenomenon or concept. Second, we assigned at least one code to each citation from a sample of 195 PrEP-related citations that were identified via a search in the PRS database. Third, by using a thematic analysis technique,[@R17] we sorted and grouped these codes into larger concept areas by reviewing the relationships to other codes and assigned a broader 'category'. Codes and categories are not mutually exclusive. In this preliminary study, we identified 19 codes that were collapsed into five categories: (1) potential PrEP user/prescriber, (2) considerations while on PrEP, (3) PrEP efficacy and safety, (4) methods of and experiences with PrEP clinical trials and (5) cost-effectiveness or economic evaluation. The following describes each of the categories with specific examples.

###### 

Mapping study topics: categories and codes with examples of study topics for each

  Categories(n=5)                                            Codes (n=19)                                     Examples of study topics
  ---------------------------------------------------------- ------------------------------------------------ -------------------------------------------
  1\. Potential PrEP user/prescriber                         Acceptability/willingness (cognition, emotion)   Barriers/facilitators/stigma to take PrEP
  PrEP willingness                                                                                            
  Feasibility of starting PrEP or programme                                                                   
  Knowledge/awareness                                        Awareness of PrEP                                
  Knowledge of PrEP                                                                                           
  Access/routine healthcare visit (structural)               Routine HIV testing                              
  Men's healthcare                                                                                            
  Feasibility of PrEP clinic                                                                                  
  PrEP candidacy/HIV risk                                    Risk perceptions                                 
  HIV testing/status                                                                                          
  Risk factors/behaviours                                                                                     
  Who benefits the most from PrEP                                                                             
  Number of sex partners                                                                                      
  PrEP eligibility                                                                                            
  2\. Consideration while on PrEP                            Adherence                                        Adherence
  Adherence measurement                                                                                       
  Retention/re-engagement in care                            Retention in care                                
  Re-engagement in care                                                                                       
  Risk compensation                                          Condomless sex while on PrEP                     
  Injection drug uses                                                                                         
  Incidence of STIs                                                                                           
  Risk perception                                            HIV risk perception while on PrEP                
  Adverse event                                              Adverse events                                   
  PrEP user issues and characteristics/PrEP uptake           PrEP uptake/use                                  
  Disclose to partner, stigma                                                                                 
  PrEP user's experience/characteristics                                                                      
  PrEP prescription/PrEP clinic                              PrEP prescribe (for provider)                    
  PrEP clinic characteristics                                                                                 
  Conception (not with birth control pill)                   PrEP interaction with hormone                    
  HIV serodiscordant couples desiring a child                                                                 
  Incidence of pregnancy                                                                                      
  Routine HIV testing/health screening                       Type and effect of HIV testing                   
  Screening for mental health problems                                                                        
  3\. PrEP efficacy and safety                               Effectiveness/safety/ drug resistance            Drug resistance
  HIV disease progression                                                                                     
  Effectiveness of PrEP                                                                                       
  PrEP safety                                                                                                 
  Estimate impact and effectiveness/drug resistance          Estimate impact of PrEP                          
  Estimate effectiveness of PrEP                                                                              
  Estimate drug resistance                                                                                    
  4\. Methods of and experiences with PrEP clinical trials   Trial' method/characteristics                    Study participants' characteristics
  Study method                                                                                                
  Trial' experience                                          Study participants' experience                   
  Experience of researchers                                                                                   
  Influence of participants' partner                                                                          
  5\. Cost-effectiveness or economic evaluation              Cost-effectiveness                               Cost-effectiveness
  Economic evaluation                                        Cost unity/benefit/minimisation                  

PrEP, pre-exposure prophylaxis; STIs, sexually transmitted infections.

### Category 1: potential PrEP user/prescriber {#s3e1}

This category will capture studies discussing behavioural aspects or criteria for potential PrEP users or providers who may be considering prescribing PrEP, but have not actually done so. Studies assigned in this category include those that report barriers and facilitators for taking or prescribing PrEP. This category consists of four codes described below.

We will assign the code *access/routine healthcare visit* to studies discussing barriers to access PrEP prescriptions or lack of feasibility of PrEP programmes due to structural issues (eg, costs to the patient, lack of providers who can prescribe PrEP or inability of healthcare providers to prescribe PrEP at point of care). Studies on other types of barriers to take PrEP (eg, barriers related to cognition and emotion such as stigma and denial) will be coded as *acceptability/willingness.* We will assign the code *knowledge/awareness* to studies assessing visibility of PrEP and *PrEP candidacy/HIV* risk to studies discussing the association between PrEP uptake and risk perceptions, frequency of HIV testing, risky behaviours and number of sex partners.

### Category 2: considerations while on PrEP {#s3e2}

This category will capture studies that report experiences of and issues/problems related to starting or staying on PrEP encountered by PrEP users or prescribers. This category consists of nine codes.

We will assign codes *adherence* to studies assessing adherence to PrEP and *retention and re-engagement in care* to studies with some aspect of retention/re-engagement in PrEP care. The code *adverse event* will be assigned to studies discussing adverse events as a barrier to taking PrEP and *risk compensation* will be assigned to studies assessing the frequency of HIV risk behaviours (eg, condomless sex, injection drug use) or reporting the incidence of STI while on PrEP. Studies assessing subjective judgments and beliefs about HIV risk while on PrEP will be coded as *risk perception.* The code *conception* will be assigned to studies reporting PrEP use among HIV-serodiscordant couples desiring a child. This category also includes studies that assess disclosure of PrEP use to partners, PrEP user characteristics and the experiences of taking PrEP other than adherence and adverse events, which will be assigned the code *PrEP user issues and characteristics/PrEP* uptake. Experiences of prescribing PrEP among healthcare providers and/or managing a PrEP clinic will be assigned the code *PrEP prescription/PrEP clinic*. Other study topics in this category include the type and effect on PrEP uptake of routine HIV testing and screening for other health issues, such as mental health disorders. These studies will be assigned the code *routine HIV testing/health screening.*

### Category 3: PrEP efficacy and safety {#s3e3}

This category will capture studies that focus on biomedical aspects of PrEP and medication efficacy, including new modes of PrEP medications (eg, type, dose and route of administration). There are two codes in this category.

We will assign the code *effectiveness/safety/drug resistance* to studies assessing medication efficacy (eg, reduction of HIV seroconversion), harms resulting from the use of medication, and sensitivity to other antiretroviral medications. Examples of studies with this code include randomised controlled trials to test PrEP efficacy as well as studies monitoring HIV disease progression among people who seroconverted while on PrEP. We will also assign the code to studies assessing the biomedical aspects of contraceptive drugs among women on PrEP (eg, drug safety or interactions). For studies simulating the impact of PrEP on HIV incidence, and drug effectiveness or resistance, we will assign the code *Estimate impact and effectiveness/drug resistance.* We anticipate that studies with this code will usually be mathematical modelling studies.

### Category 4: methods of and experiences with PrEP clinical trials {#s3e4}

This category will capture studies focusing on processes or experiences of clinical trials and contains two codes.

We will assign the code *Trial methods and characteristics* to PrEP study protocols that explain methods used in a clinical trial or intervention, or those that discuss ethical issues of conducting PrEP trials. Another example includes studies that only report baseline data. We will assign the code *Trial experiences* to studies that report trial participants' experiences (eg, stigma experienced during their participation and their partners' reactions).

### Category 5: cost-effectiveness or economic evaluation {#s3e5}

This category has two codes, *Cost-effectiveness* and *Economic evaluation*, and will capture all types of cost studies. The code *Cost-effectiveness* will be assigned to studies comparing the cost of PrEP treatment and HIV testing, and to those focusing on prompt treatment. These reports are usually mathematical modelling studies. Example of studies with the code *Economic evaluation* include studies that discuss cost utility, cost benefit, and cost minimization.

These codes and categories are considered preliminary. We will confirm and modify them as needed by using constant comparison methods that allow for continuous validation with subsequent citations through the scoping review process.[@R18]

Data analysis {#s3f}
-------------

We will summarise the codes and categories for study topics using descriptive statistics (eg, frequencies, percentages). Publication year, country where the study was conducted, population characteristics (eg, age, race, gender, sexual orientation, risk category), and research design (eg, cross sectional, randomised controlled trials, cohort) will also be analysed using descriptive statistics. We will not synthesise the findings from the included studies since our goal is to provide a scope or broad perspective of the research literature.[@R13]

Patient and public involvement {#s3g}
------------------------------

No patients and public were involved to develop this protocol.

Ethics and dissemination {#s4}
========================

This review does not require ethics approval since we are using previously published data. We will present our findings at HIV-related conferences and publish in a peer-reviewed journal.

Limitations {#s5}
===========

One limitation of our scoping review is the exclusion of non-English or grey literature. By excluding these literatures, we cannot rule out publication bias in our findings since we may be missing studies from non-English speaking countries and with negative or null findings. We will not assess study quality since it is generally considered to be optional for scoping reviews.[@R19] Due to the lag in adding and indexing articles in various online databases, our review may not include the most recent publications and may not represent the latest knowledge about PrEP. Another limitation is that we will use inclusion criteria of the included primary studies to determine study participants' characteristics, and the study's stated purposes or objectives for study topics. Thus our review will not capture other information described or implied elsewhere in the full text (eg, research sites and reported sample characteristics).

Discussion {#s6}
==========

This scoping review will contribute to the PrEP field by examining the PrEP literature to map study topics, describe study characteristics and populations and identify research gaps. In particular, the review will identify understudied populations and behavioural research topics related to PrEP that could be the focus of future primary studies. By providing a broad overview of the PrEP literature, we hope that our review will contribute to HIV prevention efforts to achieve zero new HIV infections.
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